Natera stock gains as new lung cancer study supports Signatera value

Natera stock (ISIN US6323071042) is trading on Nasdaq at USD 369.39 as of September 18, 2026, leaving the diagnostics specialist near its 52-week high and more than 60 percent above its level at the start of 2026, according to MarketBeat and Investing.com data.

New lung cancer study backs Signatera

As Simply Wall St reported on September 19, 2026, Natera presented new data from the largest minimal residual disease (MRD) study in lung cancer, covering more than 1,100 patients with resected stage 1–3 non-small cell lung cancer (NSCLC).

According to Simply Wall St, the study’s results bolster the clinical case for Natera’s Signatera MRD test in lung cancer and are part of a broader narrative that points to a fair value estimate of around USD 344 per share for Natera.

Analyst targets and valuation context

Based on data compiled by MarketBeat as of September 18, 2026, Natera carries a consensus rating described as Moderate Buy, with the average 12-month price target at USD 330.83 per share.

With Natera stock at USD 369.39 on September 18, 2026, that consensus target implies about 10.4 percent downside from the current level, illustrating how the strong rally in 2026 has pushed the share price above the average analyst target, even though most houses still rate the stock positively.

According to Investing.com on September 20, 2026, Natera shares closed at USD 369.39 in regular trading, with an after-hours indication around USD 368.20, and a 52-week range between USD 157.43 and USD 369.69, placing the latest price essentially at the top of the yearly band.

Price performance and market capitalization

MarketBeat notes that Natera’s stock was trading at USD 229.09 at the beginning of 2026, meaning the shares have risen by 61.2 percent year-to-date to reach USD 369.39 by September 18, 2026.

As of September 19, 2026, Natera’s market capitalization stands at USD 53.24 billion, according to data from CompaniesMarketCap, corresponding to a 63.36 percent increase in market cap during 2026.

For investors, the combination of a share price right at the 52-week high, a year-to-date gain of more than 60 percent and an average analyst target below the current level highlights how much future growth in MRD testing and broader molecular diagnostics is already reflected in Natera’s valuation.

Conference appearance and insider activity

Natera also remains active on the investor-relations front. The company presented at the Morgan Stanley 24th Annual Global Healthcare Conference at 7:45 a.m. Eastern Time on September 14, 2026, as documented in a transcript published by Zonebourse on September 20, 2026.

On the corporate governance side, Natera disclosed an insider share sale by officer Solomon Moshkevich, who sold 945 shares on September 16, 2026 and now holds 43,702 shares, representing about 0.03 percent of the company, according to a filing summary reported by Sina Finance on September 20, 2026.

The insider sale is modest in size relative to Natera’s USD 53.24 billion market capitalization and does not change the overall ownership structure, but it is a reminder that management is actively managing personal positions as the share price trades near record levels.

Stock holds gains near 52-week high

As of the last completed trading day on September 18, 2026, Natera stock closed on Nasdaq at USD 369.39, with the price effectively matching the 52-week high of USD 369.69 and sitting far above the 52-week low of USD 157.43, while the company’s market capitalization around USD 53.24 billion underscores how strongly the market is valuing its MRD and molecular diagnostics platform.

More news and analyses on Natera stock